BIND Therapeutics inks research agreement with Roche to discover new nanodrugs

BIND Therapeutics inks research agreement with Roche to discover new nanodrugs -

BIND Therapeutics, Inc .: Therapeutic (NASDAQ BIND), a platform of nanomedicine company stage clinical development in targeted and programmable called Accurins ^TM , today announced it has entered into a research agreement with Roche to discover new nanodrugs Accurins using for the treatment of diseases in the therapeutic areas outside oncology. The collaboration will focus on the combination of technology Accurin BIND with Roche proprietary therapeutic costs and targeting ligands.

"The addition of Roche, a global leader and innovative leader, our collaborators single family underlines the leading position of BIND in the field of nanomedicine ,," said Scott Minick, CEO of BIND Therapeutics. "combining Medicinal Nanoengineering BIND ^® platform with deep expertise Roche in areas of diseases with unmet medical needs, this valid agreement yet the vast potential of our technology and facilitates the extension of our platform into new therapeutic areas. "